Blog

Neoadjuvant therapy for resectable pancreatic cancer suggested by Alan Burguete-Torres

Photo of Alan Burguete-Torres from dralanburguete.com

Oct 7, 2024, 16:42

Neoadjuvant therapy for resectable pancreatic cancer suggested by Alan Burguete-Torres

Alan Burguete-Torres, Gastrointestinal Cancer Specialist at Centro Médico Zambrano Hellion, shared a post on X:

“New study on neoadjuvant therapy for resectable pancreatic cancer shows no improvement in overall survival rates. This highlights the need for further research to optimize treatment strategies.”

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials

Authors: Daniel Aliseda, Pablo Martí-Cruchaga, Gabriel Zozaya, Nuria Blanco, Mariano Ponz, Ana Chopitea, Javier Rodríguez, Eduardo Castañón, Fernando Pardo and Fernando Rotellar.

Source: Alan Burguete-Torres/X

Alan Burguete-Torres Ana Chopitea cancer cancer awareness cancer care Cancer research Daniel Aliseda Eduardo Castañón Fernando Pardo Fernando Rotellar fight against cancer Gabriel Zozaya Global fight against cancer Javier Rodríguez Mariano Ponz Nuria Blanco OncoDaily Oncology Pablo Martí-Cruchaga Pancreatic Cancer resectable pancreatic cancer

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage